FDA approves second drug for a site-agnostic indication; larotrectinib was tested across 17 cancer types

Vitrakvi (larotrectinib) aims to treat a very small group of people—some say fewer than 3,000 new patients a year in the U.S. And since these patients have diseases that span multiple tumor sites, finding them isn't easy.